Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to ...

The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with ...

Researchers are urging collaborators to think about the best structural resolution for their formulation models.

Pharma quality issues - need prevention-driven regulatory culture: Dr. M. Aamir Mirza Wednesday, December 3, 2025, 08:00 Hrs [IST] The concerns surrounding the quality of pharmace ...

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF ...